PTPRN2-AS1

Across TCGA pan-cancer cohorts, PTPRN2-AS1 RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of PTPRN2-AS1’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where PTPRN2-AS1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types PTPRN2-AS1 is over-expressed in tumor, although a few such as LUAD and LUSC show the opposite, repressed pattern.

KIRC, KIRP, and LUAD are the cancer types where PTPRN2-AS1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PTPRN2-AS1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Female	II,III,IV	+1.208	<.001	12	view →
KIRP	Male	All	+1.538	<.001	11	view →
LUAD	Female	II,III,IV	−1.912	<.001	9	view →
THCA	All	II,III,IV	+0.287	<.001	9	view →
LUSC	Male	All	−2.122	<.001	8	view →
STAD	All	II,III,IV	+0.730	<.001	7	view →
HNSC	All	III,IV	+0.275	.005	6	view →
PAAD	All	All	−1.285	.009	4	view →
KICH	All	All	+0.294	.006	2	view →
UCEC	All	All	−0.283	.014	2	view →
PRAD	All	All	+0.177	.018	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

PTPRN2-AS1–KIRC

Open the KIRC breakdown →